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ABSTRACT 
Stem cells have a unique ability to both self-renew and differentiate into diverse cell 
types and they harbor remarkable potential in therapeutic applications. Stem cells 
can be isolated from various sources of both embryonic and adult origin. During the 
past decade, research on stem cells has rapidly expanded, but many issues of stem 
cell biology and their clinical use remain unresolved. There is a need for methods to 
thoroughly characterize therapeutic cell populations, to better distinguish them from 
other cells, and to control variation within and between different cell preparations.  
 
The surface of stem cells, like all other human cell surfaces, is covered by a 
complex network of glycans. This is the outmost layer of cells, called the 
glycocalyx. The glycocalyx is characteristic to and different in every cell type and 
reflects even subtle changes in cell behaviour and for example cell differentiation. 
Cell surface glycans are the first cellular components encountered by approaching 
cells, pathogens, signalling molecules and other binders, making the terminal glycan 
units key players in cell interactions and signalling. Due to their prominent cell 
surface localization, glycan epitopes can be utilized for identifying and isolating 
specific cell types from heterogeneous populations.  
 
The aim of this study was to characterize relevant glycan structures on umbilical 
cord blood derived stem and progenitor cells, to study how they are regulated and to 
determine their influence on stem cell biology. As decribed in the original 
publications of this study, we were able to characterize two novel glycan 
determinants, O-GlcNAc and linear poly-LacNAc, on umbilical cord blood derived 
mesenchymal stromal cells (UCB-MSCs). We further discovered that galectins-1 
and -3 secreted by these cells are bound on the cell surface and that the cell surface 
galectin-1 interacts with P-selectin. This interaction is likely to play a role in the 
immunomodulatory homing of UCB-MSCs to sites of injury or inflammation. In 
addition, we present the effects and potential use of metabolic glycoengineering of 
UCB-MSC. 
 
Taken together, these studies provide new insights into the glycobiology of UCB 
derived stem and progenitor cells. This information may help to distinguish better 
cell populations for distinct therapeutic applications and to design therapeutic cells 
with enhanced biological properties.  
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REVIEW OF THE LITERATURE 
1. UMBILICAL CORD BLOOD STEM CELLS 
1.1 Umbilical cord blood as a stem cell source 
 
Umbilical cord blood (UCB), also called placental blood or cord blood, is the 
leftover blood that remains in the vessels of the umbilical cord and placenta after the 
birth of a baby. In the past, UCB was usually discarded as biological waste. UCB is 
collected ex utero from the cord vein by needle puncture, similar to the collection of 
peripheral blood, and the collection bag is filled by gravity. The first successfull 
human cord blood transplantation was carried out in 1988 in a patient with Fanconi’s 
anemia (Gluckman et al., 1989). Since then, UCB has been shown to contain various 
types of stem and progenitor cells (Pelosi et al., 2012). Especially it has been 
recognized as an efficient and valuable source of hematopoietic stem and progenitor 
cells for transplantation. Currently, UCB is commonly used in allogeneic 
hematopoietic stem cell (HSC) transplantation for pediatric patients and a global 
network of cord blood banks and transplant centers has been established.   
 
As a stem cell source, UCB has less ethical concerns compared to embryonic 
stem cells and has several advantages over the more commonly used bone marrow or 
peripheral blood: 1. UCB is harvested after delivery of both the infant and the 
placenta and therefore poses no risks to the donor. 2. UCB donors are thoroughly 
tested and have no known genetic or transmitted diseases, which makes UCB safe. 3. 
Stem cells in UCB are immunologically immature, therefore UCB transplantation 
permits a high degree of HLA-antigen mismatches (1 to 2 of the 6 HLA loci 
considered in UCB transplantation). 4. The collected UCB units are cryopreserved in 
cord blood banks and are therefore rapidly available for therapeutic use. 5. UCB 
transplantation induces less serious acute and chronic graft-versus-host disease while 
maintaining a strong graft-versus-leukemia effect. However, there are also two major 
disadvantages: 1. Low numbers of hematopoietic progenitor cells per UCB unit, and 
2. delayed hematopoietic recovery after transplantation followed by serious 
infections and a higher risk of graft rejection (Brown and Boussiotis, 2008, 
Gluckman et al., 2011, Pelosi et al., 2012). The advantages and disadvantages of 
different stem cell sources are listed in Table 1.  
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 Advantages and disadvantages of different stem cell sources. Adapted from (Ali and Table 1
Al-Mulla, 2012, Shtrichman et al., 2013, Liang and Zhang, 2013).  
 Advantages Disadvantages 
Pluripotent stem cells: 
Embryonic stem cells 
 
- Pluripotency: can differentiate 
into any cell type in the body 
- Ethical, religious and 
political concerns 
- Limited number of cells 
isolated from each embryo 
- High risk of transformation 
into cancer cells (teratomas) 
Pluripotent stem cells: 
Induced Pluripotent Stem 
Cells  
- Pluripotency: can differentiate 
into any cell type in the body 
- Potential for autologous cell 
replacement therapy 
 
- Slow conversion process 
- Variable efficiency of 
conversion 
- Risk of oncogene 
activation and genetic 
alterations 
Adult stem cells:  
UCB stem cells 
- No ethical, religious or 
political controversies 
- Safe and non-invasive 
collection procedure 
- Abundant supply 
- Low viral contamination 
-ability to store UCB units in 
cord blood banks 
- Lower risk of graft-versus-
host disease 
- High HLA-mismatch 
tolerance 
- Limited cell numbers per 
UCB unit 
- delayed engraftment and 
hematopoietic recovery 
-high risk of graft failure (5-
15%) 
- Multipotency: Limited 
differentiation capabilities 
 
Adult stem cells:  
Other, eg. bone marrow, 
fat 
- No ethical, religious or 
political controversies 
- Effective in generation of 
their tissue of origin 
- No risk of teratoma formation 
- Established clinical history 
 
- Invasive collection 
procedure 
- Limited cell numbers in 
human body tissues 
- Multipotency: Limited 
differentiation capabilities 
- Limited availability of 
HLA-match donors 
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1.2 Umbilical cord blood stem and progenitor cells 
Stem cells are defined as unspecialized cells that have the capacity to self-renew 
through cell division and the ability to generate diverse specialized cell types 
(Weissman et al., 2001). Progenitor cells are more restricted in their ability to 
differentiate into different cell types and can divide only a limited number of times. 
Stem and progenitor cells are present throughout life, from embryo to the adult. Stem 
cells can be classified as embryonic, fetal, adult, or induced pluripotent stem cells on 
the basis of their origin and potency. Potency specifies the potential of the stem cell 
to develop into different cell types. Pluripotent stem cells can differentiate into 
nearly all cells, whereas multipotent stem cells can differentiate only to multiple 
closely related cell types. It has been shown, that in addition to blood cells, UCB 
contains at least three different populations of stem cells: HSCs, multipotent non-
hematopoietic stem cells, and mesenchymal stromal/stem cells (MSCs)(Ali and Al-
Mulla, 2012).   
1.2.1 Hematopoietic stem cells  
 
HSCs provide a continous supply of blood cells throughout an individual’s lifetime. 
They represent a rare population of cells with an estimated frequency of 0.01% of 
total nucleated cells in the adult bone marrow. HSCs are multipotent and have the 
ability to differentiate through progenitor cells into all mature blood cell types 
including myeloid lineage cells such as granulocytes, monocytes, leukocytes, 
erythrocytes, and megakaryocytes, and lymphoid lineage cells such as T- and B-
lymphocytes (Schroeder, 2010). Hematopoiesis proceeds through an organized 
hierarchy in which a given progenitor cell population can only give rise to 
downstream populations (Figure 1).  
 
During embryonal development, HSCs are first found in the embryonic yolk sac 
and the aorta-gonad-mesonephros region, from where they migrate to the placenta, 
fetal liver and spleen. Prior to birth, HCSs migrate to the bone marrow, where blood 
cell formation is maintained throughout life. In addition to bone marrow, HCSs are 
found in low numbers in the general circulation and spleen. Also UCB has been 
found to be a very rich source of HSCs and hematopoietic progenitor cells (Pelosi et 
al., 2012). The properties of HSCs in each site differ, presumably reflecting the 
microenvironment of the cells. The microenvironment, called stem-cell “niche”, 
maintains a dynamic balance between self-renewal and differentiation and keeps the 
HSCs at a quiescent state for self-renewal (osteoblastic niche) and at an activated 
state for proliferation and/or injury repair (vascular niche) (Orkin and Zon, 2008, 
Clements and Traver, 2013). 
 
HSCs are defined by a combination of functional and phenotypical properties 
(Schroeder, 2010). Functionally, HSCs need to have the capability to multi-lineage 
differentiation and long-term self-renewal. Phenotypically, panels of cell surface 
REVIEW OF THE LITERATURE 
12 
markers are used in characterization, as single HSC specific markers have currently 
not been identified and the phenotype can vary according to the activation stage of 
the cell. Several cell surface antigens have been used in the characterization of 
HSCs. Classically HSCs are characterized by the expression of at least CD34 and 
CD133 (Bonde et al., 2004, Koestenbauer et al., 2009). Other markers that have been 
used include CD38, CD45, CD48, CD49b, CD90 (Thy-1), sca-1, Tie-2, CD105 
(endoglin), CD117 (c-kit receptor), CD150, CD201, and CD244. HSCs do not 
express lineage differentiation markers and are described as (Lin−) (Majeti et al., 
2007, Schroeder, 2010, Notta et al., 2011, Rossi et al., 2011). 
 
Stem cell therapy is a growing therapeutic modality for a variety of diseases. 
HSC transplantation is currently commonly used in the treatment of many malignant 
(e.g., leukemia, lymphoma) and non-malignant (e.g., sickle cell disease) diseases to 
replace or rebuild a patient’s hematopoietic system. In 2011 in Europe 32 075 
patients received a HSC transplant, of these 42% were allogeneic and 58% 
autologous transplants according to the European Group for Bone Marrow 
Transplantation activity survey analysis (Passweg et al., 2013). During recent years, 
peripheral blood and UCB transplants have been increasingly used as stem cell 
sources in HSC transplantation, but the primary source of HSCs is still bone marrow. 
Several clinical trials are ongoing in order to utilize HSCs in the treatment of 
autoimmune diseases, genetic diseases, and other indications. By 2013/08/14, the 
public clinical trials database http://clinicaltrials.gov listed 4324 clinical trials using 
hematopoietic stem cells world wide.  
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Figure 1 Shematic representation of hematopoiesis. Modified from Kyoto Encyclopedia of Genes and 
Genomes Pathway Database (Kanehisa et al., 2012). 
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1.2.2 Multipotent mesenchymal stromal cells  
 
MSCs are self-renewing multipotent cells that originate from the mesodermal germ 
layer. They were first identified as a subpopulation of adherent bone marrow cells 
with potential to differentiate into bone, cartilage, adipose tissue, tendon, and muscle 
in vitro (Friedenstein et al., 1968). Classically MSCs are described to have the 
potential to differentiate into connective tissues such as bone, cartilage and adipose 
tissue, skeletal muscle cells and cells of the vascular system. In addition, it has been 
demonstrated that MSCs are capable of differentiating into cardiomyocytes, neurons 
and astrocytes (Salem and Thiemermann, 2010a), (Figure 2). MSCs occur 
everywhere mesenchymal tissue turns over, therefore mesenchymal stem and 
progenitor cells have been found from various tissues such as marrow, muscle, fat, 
skin, cartilage, dental pulp, placenta and bone (Kern et al., 2006, Hoogduijn et al., 
2013). In addition, UCB represents a potentially important source of MSCs.  
 
Currently, single markers that would define MSCs have not been characterized 
and panels of both functional and phenotypic markers are combined in the 
characterization of these cell populations. Due to different origins, and various 
isolation and characterization methods of these cells, MSCs represent a heterogenous 
population in the literature and are referred to as mesenchymal stem or mesenchymal 
stromal cells (Horwitz et al., 2005, Keating, 2012). MSCs from different sources also 
display differences in for example gene expression, differentiantion potential, and 
proliferation capacity (Kern et al., 2006, Lu et al., 2006, Strioga et al., 2012).  The 
International Society for Cellular Therapy has proposed minimal criteria for defining 
human MSCs (Dominici et al., 2006). By these criteria MSCs  are characterized by 
their ability to adhere to plastic, to differentiate along osteogenic, adipogenic and 
chondrogenic lineages in vitro, and by the expression of a set of surface markers 
(positive for CD105, CD73 and CD90; negative for CD45, CD34, CD14 or CD11b, 
CD79a or CD19 and HLA-DR). In addition to the cell surface markers listed in the 
minimal criteria, several other cell surface markers have been used to characterize 
MSCs from different origins (Salem and Thiemermann, 2010a), (Table 2).  
 Cell surface markers used in the characterization of MSCs. Adapted from (Flynn et Table 2
al., 2007, Bernardo et al., 2009, Salem and Thiemermann, 2010a, Malgieri et al., 
2010). 
Positive cell surface markers Negative cell surface markers 
CD13, CD29, CD44, CD49a, -b, -c , -e, 
CD51, CD54, CD58, CD61, CD71, CD73, 
CD90, CD102, CD104, CD105, CD106, 
CD119, CD120a,-b, CD121, CD123, CD124, 
CD126, CD127, CD140a,-b, CD146, CD166, 
CD271, CD349, HLA-ABC, TRA-1-81,  
Sca-1, STRO-1, SSEA-1, SSEA-4 
CD11a, CD14, CD15, CD18, CD19, CD24, 
CD25, CD31, CD34, CD36, CD38, CD40, 
CD45, CD49d, CD50, CD62E, CD62P, 
CD80, CD86, CD117, CD133, CD144,  
HLA-DR 
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Figure 2 Schematic representation of the mesengenic process depicting mesenchymal progenitor 
cells entering distinct lineage pathways that contribute to mature tissues. Modified from 
(Caplan, 2009). 
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MSCs show great promise as a biological therapeutic for a diverse range of 
medical needs. They are especially in the focus of intense research in the field of 
regenerative medicine on the basis of their ability to 1. home to sites of damage in 
response to tissue injury, 2. promote repair through the production of trophic factors, 
3. modulate immune responses, and 4. differentiate into various cell types, resulting 
in reduction of inflammation and functional recovery of damaged tissue (Bernardo et 
al., 2012). Human MSCs characteristically lack the expression of MHC-II, CD40, 
CD80, and CD86 but express MHC-I and present themselves as nonimmunogenic. 
Although the presence of MHC-I may activate T-cells, MSCs fail to elicit immune 
responses due to the lack of costimulatory molecules (Tse et al., 2003). MSC based 
clinical trials have been conducted world wide for a variety of pathological 
conditions such as cancer, graft-versus-host disease, Crohn's disease, type I diabetes, 
stroke, spinal cord injury, Parkinson's disease, multiple sclerosis, and dilated 
cardiomyopathy. By 2013/08/07, the public clinical trials database 
http://clinicaltrials.gov listed 343 clinical trials using mesenchymal stem cells and 55 
trials using mesenchymal stromal cells. Many completed trials have demonstrated 
the safety and efficacy of MSC infusion (Wang et al., 2012).  
 
MSCs can interact with cells of both innate and adaptive immune systems and 
thereby modulate immune responses. Human MSCs suppress proliferation and 
alloreactivity of T cells, independent of T cell stimulus and the major 
histocompatibility complex, and are also able to promote the generation and 
expansion of regulatory T cells (Le Blanc et al., 2003, Glennie et al., 2005, Yang et 
al., 2009, Duffy et al., 2011). MSCs inhibit proliferation and cytotoxicity of natural 
killer (NK) cells, induce a tolerogenic, immature state in dendritic cells (DC), and 
inhibit DC generation from both monocytes and CD34
+
 precursors (Spaggiari and 
Moretta, 2013). MSCs also reduce B cell activation and proliferation (Franquesa et 
al., 2012), promote the survival of monocytes, and induce monocyte differentiation 
towards macrophage type 2 cells (Melief et al., 2013). The immunomodulatory 
properties of MSCs have been extensively reviewed in multiple reviews (Uccelli et 
al., 2008, Keating, 2012, Frenette et al., 2013, English, 2013). The main 
immunomodulatory effects and proposed mechanisms are summarized in Figure 3. 
 
The exact mechanisms of how MSCs perform their functions are currently not 
fully understood. Although MSCs exhibit prominent multi-lineage potential, and 
migrate in response to signals produced by injured or inflamed tissues, these cellular 
features appear to bear little relevance to their therapeutic effects. Instead, the 
secretion of multiple growth factors and cytokines (trophic factors) by MSCs 
provides the underlying regenerative capacity (Horwitz and Dominici, 2008, Caplan 
and Correa, 2011). Therapeutically, MSC trophic factors can be functionally 
redundant and synergistic, mediating immune regulation, cytoprotection, host stem 
cell activation and mobilization, and extracellular tissue remodeling (Lee, 2012). 
Major MSC secreted bioactive molecules and their functions are listed in Table 3. 
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Figure 3 Immunomodulatory effects of MSCs and their potential mechanisms in addition to cell-cell 
contact, (Nauta and Fibbe, 2007, Atoui and Chiu, 2012, Hao et al., 2012). CSF, colony 
stimulating factor; CTL, cytotoxic T lymphocyte; HGF, hepatocyte growth factor; IDO, 
indoleamine 2,3-dioxygenase; IL, interleukin; IFN, interferon; NK, natural killer; PGE2, 
prostaglandin E2; and TGF-β, transforming growth factor; Th1, type 1 T helper lymphocyte; 
Th2, type 2 T helper lymphocyte; TNF, tumor necrosis factor.  
 MSC secreted bioactive molecules and their functions. Modified from (Salem and Table 3
Thiemermann, 2010b, Wang et al., 2012). 
Bioactive molecule Function 
Prostaglandin-E2 (PGE2) 
 anti-proliferative  
 anti-inflammatory 
Interleukin-10 (IL10)  anti-inflammatory 
TGFβ-1, HGF  suppression of T-lymphocytes 
IL-1 receptor antagonist  anti-inflammatory 
HLA-G5 
 anti-proliferative for naïve T-
cells 
LL-37 
 anti-microbial  
 reduction of inflammation 
Angiopoietin-1 
 restoration of epithelial protein 
permeability 
MMP3, MMP9  mediates neovascularization 
Keratinocyte growth factor  alveolar epithelial fluid transport 
VEGF, bFGF, PlGF, MCP-1 
 enhancement of endothelial and 
smooth muscle cell proliferation 
IDO  T-cell suppression 
Monocytes
↓ differentiation
PGE2
B cells
↓ proliferation
↓ differentiation
↓ antibody production
Dendritic cells
↓ maturation
↓ activation
PGE2
HGF
TGF-β
PGE2
M-CSF
IL-6
IL-10
TGF-β
NK cells
↓ proliferation
↓ activation
↓ IFN-γ, TNF-α
PGE2
TGF-β
T cells
↓ proliferation
↓ activation
↓ CTL formation
↓ IFN-γ
↓ Th1
↑ Th2 production
↑ IL-4
↑ Treg
IL-4,-10
TGF-β
IDO
MSC
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MSCs exert their therapeutic effects through several different mechanisms and 
some of their effects also require direct cell-cell contact. A number of contact 
dependent mechanisms have been reported and studied in MSC immunomodulation 
including adhesion molecules (Ren et al., 2010), galectins (Sioud, 2011), Toll-like 
receptors (Lei et al., 2011), and Notch receptor signalling (Li et al., 2008, Zhang et 
al., 2009). It has also been suggested that MSCs require activation (or “licensing”) at 
the site of inflammation by inflammatory mediators released from activated immune 
cells, such as IFNγ, IL1β, and TNFα (Krampera, 2011).  
 
1.3 Umbilical cord blood banking and therapeutic use 
The first attempt to use UCB in transplantation was reported 1972 in the treatment of 
a lymphoblastic leukemia patient (Ende and Ende, 1972). UCB from eight donors 
was infused in a patient suffering from acute lymphocytic leukemia. Long-term 
reconstitution of the hematopoietic system was not demonstrated, but a transient 
alteration in red blood cell antigens in the peripheral blood was reported. The first 
successful human cord blood transplantion was performed in 1988 (Gluckman et al., 
1989). Since then, UCB stem and progenitor cells have been routinely transplanted 
for over 20 years. Cord blood banking, however, started already in the 1930s, 
collecting blood for transfusion (Halbrecht, 1939). “Banking” means the systematic 
procurement, testing, storage and organization of cord blood donations and data, 
with the aim of providing tissue for hematopoietic transplantation and transplant 
outcome data for analysis (Rubinstein, 2009). The first public cord blood bank was 
established at the New York Blood Center in 1991 (Rubinstein et al., 1999) and the 
first unrelated UCB transplantation was performed in a 4-year old child with 
leukemia in 1993 (Kurtzberg et al., 1996). Today, a global network of cord blood 
banks and transplant centers has been established. Currently, over 600,000 cord 
blood units are estimated to be stored in cord blood banks and more than 20,000 
transplants have been distributed world wide (Gluckman et al., 2011). In Finland, the 
Finnish Red Cross Blood Service collected and banked cord blood during the years 
1998-2013, and currently the Finnish Red Cross Blood Service serves as a cord 
blood transplant distributor.  
 
Medical researchers believe that stem cell therapy has the potential to 
dramatically change the treatment of human disease. UCB is increasingly used both 
as a source of stem cells for standard therapy as well as on experimental basis. At 
present, UCB transplantation has been used in the treatment of more than 80 
different diseases and thousands of patients. Most UCB transplants have been 
performed in patients with blood and immune system diseases such as leukemia, 
lymphoma and immune deficiencies. In addition, UCB transplantation has also been 
carried out for patients with various genetic or metabolic diseases. Different diseases 
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treated with CB transplantation are listed in Table 4. By 2013/08/014, 
ClinicalTrials.gov listed 826 clinical trials using cord blood. 
 
The main practical advantages of using UCB as a stem cell source are the ease of 
procurement, the absence of risk for donors, the reduced likelihood of transmitting 
infections and the ability to store fully tested and HLA typed transplants in a frozen 
state, available for immediate use (Gluckman et al., 2011). Compared with bone 
marrow derived cells, CD34+/CD38- UCB cells have longer telomere lengths and 
they proliferate more rapidly generating larger numbers of progeny cells (Delaney et 
al., 2010). A major drawback in the therapeutic use of UCB is the low cell dose per 
UCB unit. World Marrow Donor Association recommends a minimum of 2x10
7
 total 
nucleated cells (TNC)/kg recipient weight or 2x10
5
 CD34+ cells/kg recipient weight 
for UCB transplants (Welte et al., 2010). This is 10 times more than in bone marrow 
transplantation. Lower cell doses are associated with delays in engraftment and 
immune reconstitution, followed by increased rates of infectious complications and 
graft failure.  
 
Several methods have been investigated to overcome UCB graft cell dose 
limitation and to improve the kinetics and efficacy of UCB engraftment. Research 
strategies have included ex vivo expansion of UCB HSCs and addition of third-party 
mesenchymal cells (Zaker et al., 2013, Lee et al., 2013), infusion of two UCB grafts 
(Wallet et al., 2013), modulation of CD26 expression (Christopherson et al., 2007, 
Campbell et al., 2007b), guidance of cells via magnetic nanoparticles in a magnetic 
field (Chen et al., 2013), intrabone delivery of HSCs (Frassoni et al., 2008), and 
HSC priming to enhance homing and engraftment (Sangeetha et al., 2012, Brunstein 
et al., 2013). Currently, due to the low numbers of cells in UCB transplants, UCB 
transplantation remains significantly more successful in children weighing less than 
40kg than in adult patients and children weighing more than 40kg (Tung et al., 2010, 
Delaney et al., 2010). 
 
 Medical conditions treated with UCB transplantation. Modified from New York Blood Table 4
Center's National Cord Blood Program nationalcordbloodprogram.org. 
Diagnosis for transplantation 
Leukemias 
 Acute lymphoblastic leukemia  
 Acute myelogenous leukemia  
 Acute biphenotypic leukemia  
 Chronic lymphocytic leukemia  
 Chronic myelogenous leukemia  
 Chronic myelomonocytic leukemia  
 Juvenile chronic myelogenous leukemia  
 Juvenile monomyelocytic leukemia 
 Leukemia, unspecified 
Bone marrow failure syndromes 
 Amegakaryocytic thrombocytopenia 
 Diamond-Blackfan anemia 
 Dyskeratosis congenita 
 Fanconi's anemia  
 Parxysmal nocturnal hemoglobinuria  
 Reticular dysgenesis  
 Severe aplastic anemia, unspecified  
 Shwachman-Diamond syndrome 
 Sideroblastic anemia 
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Lymphomas 
 Non-Hodkin´s lymphoma 
 Hodkin´s disease 
 Epstein-Barr virus / 
Lymphoproliferative disease 
 Autoimmune lymphoproliferative 
disease 
 Lymphoma, unspecified 
Histiocytosis  
 Familial erythrophagocytic 
Lymphohistiocytosis  
 Hemophagocytic lymphohistiocytosis  
 Hemophagocytic syndrome  
 Histiocytosis  
 Langerhans cell histiocytosis 
(histiocytosis-X)  
 X-linked lymphoproliferative disease 
Platelet Disorders  
 Congenital thrombocytopenia  
 Glanzmann's thrombasthenia 
Porphyria  
 Congenital erythropoietic porphyria 
Autoimmune diseases  
 Systemic lupus (SLE) 
Myelodysplasias 
 Myelodysplastic syndrome 
 Myelofibrosis 
Hemoglobinopathies  
 Sickle cell disease  
 Thalassemia 
 Metabolic/storage diseases  
 MPS, not specified  
 Hurler disease (MPS type IH)  
 Hurler-Scheie disease (MPS type IS)  
 Hunter's syndrome (MPS type II)  
 Sanfilippo disease (MPS type III)  
 Morquio syndrome (MPS type IV)  
 Maroteaux-Lamy syndrome (MPS type 
VI)  
 Adrenoleukodystrophy  
 Alpha-mannosidosis  
 Amyloidosis  
 Aspartylglucosaminuria  
 Austin's disease (multiple sulfatase 
deficiency)  
 Fucosidosis  
 Gangliosidosis  
 Gaucher's disease  
 I-cell disease (inclusion cell disease)  
 Infantile ceroid lipofucoscinosis  
 Krabbe disease  
 Lesch-Nyhan syndrome  
 Metachromatic leukodystrophy  
 Neiman-Pick disease  
 Osteopetrosis  
 Sandhoff disease  
 Sialidosis  
 Tay Sach disease  
 Wolman disease 
Immune deficiencies  
 Common variable immune deficiency  
 Congenital immune deficiency  
 DiGeorge syndrome  
 Griscelli syndrome  
 Lymphocyte adhesion disease  
 Nezelof syndrome  
 Omenn syndrome  
 Severe combined immune deficiency 
(SCID)  
 Wiskott-Aldrich syndrome  
 X-linked hyper-IgM syndrome  
 X-linked immune dysregulation 
 Polyendocrine enteropathy 
Neutrophil Disorders  
 Chediak-Higashi syndrome  
 Chronic granulomatous disease (CGD)  
 Congenital neutropenia  
 Kostmann syndrome 
Other Malignancies  
 Breast cancer  
 Multiple myeloma (plasma cell 
disorder)  
 Neuroblastoma  
 Other malignancy 
Other  
 Epidermolysis bullosa 
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1.4 Homing and engraftment of stem and progenitor cells 
The regeneration of tissue after transplantion is a function of proper engraftment of 
transplanted cells. In clinical settings, the optimal route for administration of stem 
cells depends on the anatomy and the extent of damage of the involved tissue or 
organ, offering a choice between two approaches: direct local or intralesional 
implantation versus systemic intravascular administration. Local implantation is 
invasive, and can disrupt a highly complex and delicate structure of the local 
regulatory microenvironment i.e., the niche, causing additional traumatic injury and 
inflammation. Systemic delivery on the other hand is limited by the difficulty of 
delivering sufficient numbers of cells to the target areas. 
 
 Recent studies have indicated that stem cells utilize similar mechanisms as 
leukocytes when transmigrating to target tissues. Leukocyte extravasation involves a 
well-characterized cascade of rolling, activation, and adhesion events (Carman and 
Springer, 2008). Soluble chemokines direct and attract stem cells toward the relevant 
sites and homing of stem cells depends on a complex interplay between chemokines, 
chemokine receptors, intracellular signaling, adhesion molecules and proteases. In 
the case of HSC transplantation, cells infused into peripheral blood respond to 
chemotactic stromal derived factor 1 (SDF-1, CXCL12) gradient from the bone 
marrow, attach to the bone marrow endothelium via integrins, selectins and other 
adhesion molecules, transmigrate through the basal membrane in a 
methylprednisolone-dependent manner, and finally home to a niche were they can 
survive, expand and proliferate, or engraft (Sahin and Buitenhuis, 2012, Suarez-
Alvarez et al., 2012). A schematic representation of stem cell homing to the bone 
marrow is presented in Figure 4. 
 
 
Figure 4 Schematic representation of HSC homing to the bone marrow. Modified from (Sahin and 
Buitenhuis, 2012). 
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After intravenous delivery of MSCs, the cells become massively entrapped in the 
lungs and filtering organs such as the liver and kidney (Kang et al., 2012). The 
mechanism of MSC homing to sites of injury or inflammation is currently under 
investigation and the exact role of MSC homing and migration for their therapeutic 
effects is unclear (Sohni and Verfaillie, 2013). However, it is believed that MSC 
homing to inflamed or injured tissues significantly increases the feasibility of 
cellular therapy. MSCs also possess a natural ability to home to and integrate into 
tumors (Droujinine et al., 2013). Tumor cells can recruit MSCs from local and 
distant sources by releasing cytokines such as vascular endothelial growth factor 
(VEGF), SDF-1 and angiopoietin 2. MSCs have both tumor-supporting roles as well 
as antitumor properties. They can incorporate into tumors and are believed to form 
part of their microenvironment (Keung et al., 2013, Reagan and Kaplan, 2011, Sun 
et al., 2014). Several molecular pathways involved in MSC homing have been 
suggested including CD44, several cytokines and chemokines, involvement of the 
chemokine receptor CXCR4, integrins, and selectins (Deak et al., 2010, Kang et al., 
2012). MSC transmigration may also involve membrane blebbing and VCAM-1 
(vascular cell adhesion molecule 1) to establish interactions with the endothelium 
(Teo et al., 2012). The glycobiological aspects of stem cell homing are further 
discussed in chapter 2.3.4. 
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2. GLYCOBIOLOGY 
The outmost layer of all cells is a dense glycocalyx that is composed of a complex 
network of carbohydrates linked to proteins and lipids decorating the cell surface. 
This layer is characteristic and specific for every cell type and the differential display 
of cell surface glycans make up cell type specific signature features (Cummings, 
2009). The glycans on cell surface diversify and fine tune the functions of cell 
surface proteins and lipids; they modulate and mediate signals in and out of cells, 
serve as receptors, and participate in multiple adhesion related events. The glycome 
of a given cell type is dynamic and changes rapidly in response to intrinsic and 
extrinsic signals. A schematic view of a cell surface decorated by glycans is 
presented in Figure 5. 
 
 
Figure 5 Artist’s view of the cell surface. Image: Lasse Rantanen / Finnish Red Cross Blood Service 
2.1 Glycosyltransferases 
Glycans are composed of variable carbohydrate chains. Unlike proteins, glycan 
chains are not primary gene products that are encoded directly in the genome. 
Instead, there are genes in the human genome that are dedicated to producing 
glycosyltransferases that assemble monosaccharides into chains in the endoplasmic 
reticulum (ER) and Golgi compartments of a cell. Glycosyltransferases are enzymes 
that catalyse the transfer of sugar moieties from activated donor molecules to 
specific acceptor molecules, forming glycosidic bonds. Linear and branched glycan 
chains are generated by the sequential action of glycosyltransferases and 
glycosidases and they are attached to proteins, lipids, and numerous small molecules.  
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The glycosyltransferases constitute one of the largest and most diverse groups of 
enzymes in nature, representing 1–2% of the human genome (Rini et al., 2009). The 
families of structurally-related catalytic and carbohydrate-binding modules (defined 
by primary sequence analysis) or functional domains of enzymes that degrade, 
modify, or create glycosidic bonds are listed in the carbohydrate-active enzymes 
database (CAZy, www.cazy.org). In October 2013 the database contained ~120 000 
entries for glycosyltransferase modules, divided into 94 families. However, most of 
these are uncharacterized open-reading frame sequences. The human genome 
comprises 225 glycosyltransferase sequences split into 43 families. The majority of 
glycosyltransferases utilize activated nucleotide-sugars as donors of a carbohydrate 
residue that is transferred to the acceptor but also lipid phosphate sugars and 
phosphate sugars can be utilized as donors. A conserved three-dimensional structure 
has been characterized for all nucleotide sugar dependent glycosyltransferases 
exhibiting only two types of folds, termed GT-A and GT-B, while 
glycosyltransferases utilizing lipid-phosphate donor substrates have a completely 
different three-dimensional architecture (Hansen et al., 2010, Breton et al., 2012). 
 
The repertoire of glycosyltransferases in genomes is believed to determine the 
diversity of cellular glycan structures since a different glycosyltransferase is required 
for each distinct glycosidic linkage that is formed and for each sugar that is 
transferred. It is known that a major mode of regulating cellular glycosylation is the 
transcriptional regulation of enzymes involved in glycan synthesis and catabolism. 
Therefore the expression of glycan epitopes on the cell surface can, in many cases, 
be correlated with the expression and activity levels of appropriate 
glycosyltransferases. However, numerous factors can impact individual 
glycosylation steps on proteins and lipids, including enzyme accessibility to glycan 
modification sites, the abundance of acceptors, the availability of sugar-nucleotide 
precursors, and relative levels of active enzymes that can compete for the same 
substrates (Comelli et al., 2006, Nairn et al., 2008).  
2.2 Glycan diversity 
Glycan chains on proteins and lipids are extremely variable and represent numerous 
combinatorial possibilities. Glycoprotein and lipid molecules can carry differential 
glycans and appear in differential glycoforms while having identical amino acid or 
lipid compositions. It has been estimated that the full diversity of mammalian 
glycans comprises over 7 000 structures, assembled from ten different 
monosaccharides: fucose (Fuc), galactose (Gal), glucose (Glc), N-
acetylgalactosamine (GalNAc), N-acetylglucosamine (GlcNAc), glucuronic acid 
(GlcA), iduronic acid (IdoA), mannose (Man), sialic acid (predominantly N-
acetylneuraminic acid, Neu5Ac, in humans) and xylose (Xyl) (Cummings, 2009). 
Complex glycans are divided into distinct classes according to their core structure 
and the type of linkage through which they are attached to proteins or lipids (Figure 
6). Although different glycan classes have unique core regions, by which they are 
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distinguished, the outer structural sequences can be shared among different classes 
of glycans (Moremen et al., 2012). 
 
 
 
 
 
 
 
 
Figure 6 Schematic representation of common classes of animal glycans. Abbreviations: fucose (Fuc), 
galactose (Gal), glucose (Glc), N-acetylgalactosamine (GalNAc), N-acetylglucosamine 
(GlcNAc), glucuronic acid (GlcA), iduronic acid (IdoA), mannose (Man), and xylose (Xyl) 
Modified from (Varki and Sharon, 2009, Moremen et al., 2012).  
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2.2.1 Glycoproteins 
 
A glycoprotein is a glycoconjugate in which a protein carries one or more glycans 
covalently attached to a polypeptide backbone. Glycans can be attached to 
asparagine (Asn) side chains in polypeptide structures through amide linkages (N-
glycosylation) in the sequon Asn-X-Ser/Thr (where Ser is serine, Thr is threonine, 
and X represents any amino acid exept proline), through O-glycosidic linkages to Ser 
and Thr side chains, hydroxylysine (collagen), tyrosine (glycogenin), or through C-C 
linkages to the C2 position of tryptophan (C-mannosylation) (Moremen et al., 2012). 
It has been estimated that approximately half of all human proteins are 
glycoproteins, and most of those contain N-glycan structures. 
 
N-glycans share a common core pentasaccharide composed of three mannose and 
two N-acetylglucosamine residues, and are further classified into three main classes: 
high-mannose (or oligomannose) type, complex type, and hybrid type (Stanley et al., 
2009) (Figure 6). N-glycans are synthesized and modified in the lumen of ER and 
Golgi compartments, and the diversity of N-glycans is determined mainly by 
variable terminal monosaccharides. N-glycans occur on many secreted and 
membrane-bound glycoproteins, regulating and fine tuning a variety of their 
functions. Intracellularly N-glycosylation plays a role in the quality control of 
protein folding in the lumen of ER. A complete absence of N-glycans is lethal and 
defects in N-glycan synthesis and processing result in various congenital disorders 
(Theodore and Morava, 2011, Woods et al., 2012). 
 
O-glycans are covalently linked to the hydroxyl group of serine and threonine 
residues of glycoproteins and can be extended into a variety of different structural 
core classes (Brockhausen et al., 2009). Mucin-type O-linked α-N-
acetylgalactosamines (O-GalNAc) are the most commonly found O-glycans. There 
are also several types of nonmucin O-glycans, including α-linked O-Fuc, β-linked O-
Xyl, α-linked O-Man, β-linked O-GlcNAc (N-acetylglucosamine), α- or β-linked O-
Gal, and α- or β-linked O-Glc glycans. O-glycans are less branched than most N-
glycans, and are commonly biantennary structures that have variable termini that 
may be similar to the termini of N-glycans (Figure 6). Single O-GlcNAc has been 
considered as an intracellular modification that cooperates with phosphorylation in 
the cytosol to regulate a variety of cellular processes including intracellular 
signaling, cytokinesis, and transcription (Zachara and Hart, 2006, Hart et al., 2011). 
Recently O-GlcNAc has also been found extracellularly (Matsuura et al., 2008).  
2.2.2 Glycosphingolipids 
 
Glycosphingolipids (GSL, often also called glycolipids) consist of a glycan usually 
attached via glucose or galactose to the terminal primary hydroxyl group of the lipid 
moiety ceramide (Schnaar et al., 2009). The ceramide fatty acid composition is 
heterogenous and GSLs are further classified into five major series defined by their 
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internal core carbohydrate. These are ganglio (GalNAcβ1-4Gal), globo (Galα1-
4Gal), lacto (Galβ1-3GlcNAc β1-3Gal), and neolacto (Galβ1-4GlcNAcβ1-3Gal) 
series, and gangliosides, which are the sialic acid containing acidic GSLs, that for 
the most part, are based on the ganglio series (Lingwood, 2011). GSLs are found in 
the outer leaflet of cell membranes of organisms from bacteria to man, with their 
glycans facing the external milieu (Figure 6). GSLs are not uniformly distributed in 
the membrane, but cluster in cell surface microdomains i.e. lipid rafts, caveolae and 
glycolipid-enriched microdomains (Anderson, 1998, Simons and Toomre, 2000, 
Yanagisawa, 2011). GSLs are ubiquitously expressed in animal tissues but are most 
abundant in the nervous system. Their functions fall into two major categories: 
mediating cell–cell interactions via binding to molecules on apposing plasma 
membranes (trans recognition) and modulating activities of proteins in the same 
plasma membrane (cis regulation) (Schnaar et al., 2009). 
2.3 Lectins 
Glycans can mediate a wide variety of biological roles by virtue of their physical 
properties such as mass, shape, and charge. However, many of their more specific 
biological roles are mediated via recognition by glycan binding proteins, lectins 
(Gabius, 2008). In some instances, glycans may also interact with other glycans. The 
best known are interactions between Lewis x structures (Galβ1-4[Fucα1-3]GlcNAc) 
(Hakomori, 2004, Bucior and Burger, 2004). Lectins were first discovered more than 
100 years ago in plants, but they are now known to be present throughout nature. A 
lectin molecule contains at least one carbohydrate-binding site, and they may be 
soluble or membrane-bound proteins or glycoproteins. Most lectins can be classified 
into several subgroups or families with defined carbohydrate-recognition domains 
(CRDs) having a conserved amino acid sequence or three-dimensional structure. 
Major types of animal lectins are schematically presented in Figure 7. Lectins 
recognize commonly specific termini of glycan chains, but the structures of glycans 
recognized by members of a single lectin family can be diverse. Specific 
oligosaccharides are associated with a certain cell type or organelle, so lectins that 
bind to specific configurations of sugar moieties can thus serve to identify different 
cell types and cellular components (Varki et al., 2009). 
 
Galectins are a family of evolutionarily-conserved animal lectins defined by at 
least one CRD of 130 amino acids, with affinity for beta-galactosides and conserved 
sequence motifs. The minimal glycan structure recognized by galectins is N-
acetyllactosamine (LacNAc, Galβ1-4GlcNAc). 15 Galectins have been identified in 
mammals (Cummings and Liu, 2009). They function both intracellularly, influencing 
intracellular signalling pathways through protein–protein interactions with other 
cytoplasmic and nuclear proteins, and extracellularly. Galectins are differentially 
expressed in different tissues and cell types. The galectins do not contain classical 
secretory signals, but some members are released to the extracellular compartment 
through an unusual route requiring intact carbohydrate binding (Seelenmeyer et al., 
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2005). Outside the cell, the galectins bind multiple glycosylated cell-surface and 
extracellular matrix binding partners and form ordered galectin-glycan structures, 
lattices, on the cell surface. These lattices regulate cell adhesion, migration, 
proliferation, survival, and differentiation, by organizing the localization of cell 
surface receptors, glycolipids and glycoproteins. (Rabinovich and Toscano, 2009, Di 
Lella et al., 2011). Galectins play important roles in diverse physiological and 
pathological processes, including immune and inflammatory responses, tumour 
development and progression, neural degeneration, atherosclerosis, diabetes, and 
wound repair (Yang et al., 2008).  
 
 
Figure 7 Schematic representation of some major types of animal lectins. Abbreviations: (CRD) 
carbohydrate-recognition domain; (EG) EGF-like domain; (IG2) immunoglobulin C2-set 
domain; (TM) transmembrane region; and (C3) complement regulatory repeat. The number 
of domains underlying the CRD can vary among family members. Modified from (Varki et al., 
2009). 
Selectins are a family of mammalian lectins that share an N-terminal, calcium-
dependent lectin domain. The selectin family contains three members: E-, P- and L-
selectin (CD62E, -P, and -L). L-selectin is expressed on mature leukocytes and 
hematopoietic stem cells, P-selectin is expressed on platelets and endothelium, and 
E-selectin is expressed only on endothelium. All three selectins bind to sialic acid 
and fucose containing glycans, the prototype of which is the tetrasaccharide known 
as sialyl Lewis x (sLex, Neu5Acα2-3Galβ1-4[Fucα1-3]GlcNAc). P-selectin is an 
important player in the initial recruitment of leukocytes to tissues with injury due to 
inflammation. When cells are activated during inflammation, intracellular P-selectin 
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is transported within minutes to the vascular endothelial cell or platelet surface from 
intracellular storage granules (Lasky, 1992, Varki, 1994). The main physiological 
ligand for P-selectin is P-selectin glycoprotein ligand-1 (PSGL-1), which is 
concentrated on the tips of microvilli on leukocyte cell surfaces. The optimal binding 
of P-selectin to PSGL-1 is dependent on sialyl sLex on a specific core 2 O-glycan 
and three adjacent sulphated tyrosine residues. P-selectin has also been shown to 
bind weakly to some forms of heparan sulphate and to some other glycoproteins 
bearing the sLex determinant (Moore et al., 1992, Norgard et al., 1993, Leppanen et 
al., 2000).  
2.4 Glycobiology of therapeutic stem cells 
Complex carbohydrates cover all cellular surfaces and serve a wide range of 
biological functions in cells and tissues. Their biosynthesis involves more than 200 
distinct glycosyltransferases in human cells, and the expression, properties, and 
topology of these enzymes regulate the glycosylation patterns of proteins and lipids. 
Data collected on cell surface glycans can be exploited to isolate, characterize and 
identify different cell populations, as well as to detect subtle changes in cell behavior 
and differentiation status. In addition to providing specific features to the cell 
surface, carbohydrates are important components of extracellular matrices and 
especially proteoglycans participate in providing an interface between cells and their 
surrounding microenvironment. Furthermore, owing to the optimal positioning of 
cell surface glycans, engineering of cell surface glycosylation can be used for 
example to reduce immunogenity, to alter proliferation, or to influence the 
biodistribution of therapeutic cells. 
2.4.1 Stem cell glycome 
 
Stem and progenitor cell lineages display characteristic glycosylation patterns that 
distinguish them from differentiated cell types (Lanctot et al., 2007, Fujitani et al., 
2013). Typical glycosylation features of human embryonic stem cells, revealed by 
structural analysis, include abundant terminal α-mannose and LacNAc residues, both 
α2,3- and α2,6-sialylation, complex N-glycan core and peripheral fucosylation, and 
the presence of biantennary as well as branched complex-type N-glycans. The most 
abundant complex fucosylated structures were found to be Lewis x and H type 2 
epitopes on N-glycans (Satomaa et al., 2009). Furthermore, the core structures of 
glycolipids switch from globo- and lacto to ganglio-series during human embryonic 
stem cell differentiation (Liang et al., 2010, Fujitani et al., 2013).  
 
Also HSCs and MSCs harbour distinct cell surface glycan structures. The 
glycosylation characteristics of UCB derived hematopoietic CD133+ cells include 
increased biantennary, high-mannose and complex-type N-glycans, α2,3-sialyl-N-
acetyllactosamine structures, and decreased hybrid-type and monoantennary N-
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glycans (Hemmoranta et al., 2007). Genes associated with the glycosylation 
characteristics of UCB derived CD133+ cells were found similarly expressed in 
CD34+ cells, which suggests similar glycosylation pattern in both progenitor cell 
types (Hemmoranta et al., 2006).  
Bone marrow-derived MSC enriched glycan features include high-mannose type 
glycans, linear poly-N-acetyllactosamines, stage-specific embryonic antigen 4 
(SSEA-4), GM3/GD3-type glycolipids, sLex, and α2,3-sialylation (Heiskanen et al., 
2009, Hamouda et al., 2013). However, some differences exist between MSCs 
derived from different origins: UCB-MSCs have been found to contain more 
fucosylated structures and high-mannose type N-glycans than bone marrow-MSCs, 
and only bone marrow-derived MSCs express ganglioside GD2 (Martinez et al., 
2007, Nystedt et al., 2013). Taken together, abundance of high mannose-type N-
glycans and α2,3-sialylation appear to be common features of human embryonic 
stem cell, HSC and MSC glycomes.  
 
Cell isolation and culture conditions affect primary cells and can modify their 
cell surface phenotype (Qian et al., 2012). Especially animal products used in cell 
culture medium cause dramatic alterations within cell surface glycans. Most widely 
studied is the incorporation of the non-human sialic acid Neu5Gc (N-
glycolylneuraminic acid) into cell surface glycans from animal derived products 
such as animal plasma derived glycoproteins used in cell culture and separation 
reagents (Martin et al., 2005, Heiskanen et al., 2007). The two most common 
mammalian sialic acids are Neu5Gc and Neu5Ac, with Neu5Ac being the metabolic 
precursor of Neu5Gc. Humans are genetically unable to produce Neu5Gc from 
Neu5Ac due to an inactivating mutation in CMAH (cytidine monophosphate-N-
acetylneuraminic acid hydroxylase), the enzyme that converts Neu5Ac into Neu5Gc 
(Varki, 2001). Instead, Neu5Gc is metabolically incorporated into human cells and 
accumulates biosynthetically into cell surface glycoconjugates. Most healthy humans 
have circulating antibodies specific for Neu5Gc. Therefore, the uptake and 
expression of Neu5Gc on the surface of therapeutic cells could trigger an immune 
response upon transplantation and thereby compromise transplantation success. 
2.4.2 Glycan markers of stem cells 
 
The expression patterns and levels of glycosyltransferases and glycosidases, which 
regulate the expression of glycan epitopes on the cell surface, change drastically 
during development and are strictly controlled by transcription factors and most 
probably modified epigenetically. Therefore, glycan epitopes can serve as stage-
specific molecular markers of developing cells. Many commonly used cell surface 
antigens are carbohydrate structures attached to proteins and lipids, eventhough their 
exact functions are poorly understood. Among glycan based markers of stem cells 
are the stage-specific embryonic antigens (SSEA)-1, -3, -4 and -5 and tumor-
rejection antigen (TRA)-1-60 and -1-81, which are expressed in specific 
combinations by undifferentiated pluripotent stem and progenitor  cells, and vanish 
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upon differentiation. Polysialic acid (PSA) on neural cell adhesion molecule 
(NCAM) is also developmentally regulated and a prominent cell-surface glycan 
marker for neural stem cells (Lanctot et al., 2007) (Figure 8).  
 
SSEA-3 and -4 are generally used markers of human embryonic stem cells, and 
have also been described in mesenchymal stem cells from different origins (Gang et 
al., 2007, Guillot et al., 2007, Sun et al., 2007, Sobiesiak et al., 2010). They are 
carbohydrate epitopes of globoseries glycosphingolipids (Figure 8), and were 
originally discovered on the surface of embryonal carcinoma cells (Kannagi et al., 
1983). It has been suggested that these two glycosphingolipid epitopes play an 
important role in early embryogenesis, but no specific function for 
glycosphingolipids carrying the SSEA-3 and -4 epitopes has been identified. SSEA-4 
has been suggested as a general "stemness" marker for adult MSCs (Gang et al., 
2007). It is known that SSEA-3 is extinguished more rapidly from the cell surface 
than SSEA-4, if glycosphingolipid synthesis is blocked by inhibitors, or during 
embryonic stem cell differentiation. Depletion of these two epitopes from human 
embryonic stem cells has no apparent effect on the pluripotency characteristics of 
these cells (Draper et al., 2002, Brimble et al., 2007). Of other glycolipids, e.g. 
ganglioside GD2 is distinctively expressed by MSCs in human bone marrow, and 
can be used to differentiate MSCs from other cell types (Martinez et al., 2007).  
 
 
Figure 8 Schematic representation of some common glycans markers used for the identification and 
purification of stem and progenitor cells. Whenever possible the glycan epitope is highlighted 
by a light blue circle. Modified from (Lanctot et al., 2007). 
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The monoclonal antibodies Tra-1-60 and Tra-1-81 recognize carbohydrate 
epitopes, and are widely used markers of pluripotent human stem cells (International 
Stem Cell Initiative et al., 2007). It has been suggested that the Tra-1-81 and Tra-1-
60 antibodies recognize sialylated keratan sulfate epitopes (Badcock et al., 1999) 
potentially carried by podocalyxin (Schopperle and DeWolf, 2007), or a specific 
type 1 lactosamine epitope, which is present in human embryonic stem cells as a part 
of a mucin-type O-glycan structure (Natunen et al., 2010).  
2.4.3 Selectins in stem cell homing 
 
The goal of stem cell-based therapies is to achieve adequate tissue colonization at 
requisite anatomic locations. Recruitment of circulating cells to any anatomic site 
involves a coordinated sequence of events (Figure 4) and is mediated by specific cell 
surface molecules and soluble chemokines that direct or attract cells toward the 
relevant sites. The most potent effectors of tethering and rolling of circulating cells 
are the selectins and their ligands. Specific glycoforms of selectin ligands have been 
shown to play a crucial role in stem cell homing. 
 
HSCs display several distinct glycoforms of E-selectin ligands. CD44 is found on 
the surface of most human cells, but the expression of a sLex-decorated glycoform 
of CD44, E-/L-selectin ligand (HCELL, hematopoietic cell E-/L-selectin ligand), is 
restricted to hematopoietic stem and progenitor cells (Dimitroff et al., 2001a, 
Dimitroff et al., 2001b). HSCs display also a sLex bearing glycoform of CD43 and a 
PSGL-1 glycoform, CLA (cutaneous lymphocyte antigen), bearing abundant sLex on 
O-glycans (Merzaban et al., 2011). It has been shown that expression of especially 
HCELL confers high efficiency HSC trafficking to bone marrow through the 
engagement of endothelial E-selectin, followed by activation of very late antigen-4 
adhesion to its ligands VCAM-1 or fibronectin. Therefore, HCELL has been 
designated as the human “bone marrow homing receptor” (Sackstein, 2012a, 
Sackstein, 2012b). 
 
The exact mechanisms of MSC homing are currently still under investigation. It 
is known that adhesion molecules on the cell surface such as fucosylated selectin 
ligands influence the biodistribution of MSCs (Nystedt et al., 2013). Intravenously 
infused MSCs have been shown to become massively entrapped in the lung (Gao et 
al., 2001, Schrepfer et al., 2007), where P-selectin has been found to be 
constitutively expressed in endothelial cells (Feuerhake et al., 1998). P-selectin is 
known to play a role in MSC rolling and adherence to endothelial cells (Ruster et al., 
2006), as well as in targeting MSCs to infarcted tissues (Yilmaz et al., 2011). 
However, MSCs lack the expression of PSGL-1, the main ligand of P-selectin, and 
MSCs do not carry the HCELL isoform of CD44. Furthermore, it is known that the 
expression of adhesion molecules by MSCs is altered after ex vivo expansion 
(Sackstein et al., 2008, Qian et al., 2012).  
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2.4.4 Stem cell glycoimmunology 
 
Human MSCs suppress proliferation and alloreactivity of T cells, interfere with DC 
differentiation, activation and maturation, suppress proliferation of NK cells and 
modulate B cell functions (Figure 3). Several signaling molecules, enzymes, and 
soluble molecules, many of which are either glycoproteins or carbohydrate binding 
proteins, contribute to these effects. Galectins are a family of 15 mammalian lectins, 
involved in the regulation of innate and adaptive immune responses by human 
MSCs. Human bone marrow-MSCs express constitutively galectins -1, -3, and -8 
and upregulate galectin -9 expression upon IFN- stimulation (Gieseke et al., 2010, 
Sioud, 2011, Ungerer et al., 2013).  
 
Galectins -1 and -3 are constitutively expressed and secreted by MSCs and have 
been reported as key players of MSC mediated immunosuppression (Sioud et al., 
2011). Galectin-1 is a prototype galectin with high affinity for terminal LacNAc 
units in complex-type N-glycans (preferentially on tri- and tetra-antennary N-
glycans) (Hirabayashi et al., 2002, Rabinovich and Toscano, 2009). It has been 
shown that soluble galectin-1 from MSCs inhibits T-cell proliferation through 
neuropilin-1 binding (Lepelletier et al., 2010). MSCs also promote a shift from a 
proinflammatory Th1 toward a more anti-inflammatory Th2 T-cell response by 
secreting galectin-1 that modulates the release of the proinflammatory cytokines 
TNF-α, IFN-γ, IL-2 and IL-12, and the anti-inflammatory cytokines IL-4, IL-10 and 
IL-13 (Gieseke et al., 2010). These effects are independent of the T cell stimuli used 
and cell-cell contact may enhance the effect by upregulating MSC galectin-1 
expression (Najar et al., 2010). Galectin-3 is a chimera type galectin with one CRD 
fused to a non-lectin domain. Galectin-3 binds to terminal as well as internal 
LacNAc units and the affinity of galectin-3 to its ligands increases with multiple 
consecutive lactosamine units (Stowell et al., 2008, Rabinovich and Toscano, 2009). 
It has been shown that MSCs upregulate the expression of galectin-3 in response to 
toll-like receptor-2 activation and that galectin-3 participates in the 
immunosuppressive effects of MSCs (Sioud et al., 2010, Liu et al., 2013). 
 
Galectin-9 is a 36kDa tandem-repeat galectin. It has affinity for branched N-
glycans with repeated LacNac units, and some glycosphingolipids including GA1 
and GM1 (Rabinovich and Toscano, 2009). MSCs upregulate galectin-9 expression 
after activation with IFN-γ and galectin-9 mediates the anti-proliferative and 
functional effects of MSCs on T cells and B cells (Ungerer et al., 2013). It has been 
proposed that the expression of galectin-3 or galectin-9 by MSCs could serve as 
possible biomarkers to predict a higher or lower immune modulatory potential of 
MSC preparations and therefore to distinguish the therapeutic potency of MSCs 
derived from different donors (Liu et al., 2013, Ungerer et al., 2013).  
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2.4.5 Glycan engineering 
 
Cell surface glycans and glycan epitopes can be ex vivo modified to optimize the 
functions of therapeutic cells. Modification of cellular glycans can for example 
reduce the immunogenity or alter the proliferation of therapeutic cells, as well as 
influence their biodistribution. Several approaches can be used to achieve this goal, 
including enzymatic modification, metabolic glycoengineering, and covalent or non-
covalent coupling of glycan carrying proteins, lectins or other substrates to the cell 
surface (Campbell et al., 2007a). 
 
Metabolic oligosaccharide engineering is a technology in which non-natural or 
natural monosaccharide analogs are fed into the biosynthetic flux and thereby 
metabolically incorporated into cell surface glycoconjugates. This process is 
essentially reversible, and modified glycans can be removed from the cell surface by 
feeding the cells with counterparts over several days. The glycan biosynthetic 
machinery tolerates certain unnatural modifications of metabolic substrates, for 
example nonnatural analogs of GalNAc, GlcNAc, N-acetylmannosamine (ManNAc), 
Neu5Ac, cytidine monophospho-Neu5Ac, and fucose have been successfully 
incorporated into cell surface glycoconjugates. Metabolic influx of monosaccharide 
analogs can also be used to introduce chemically reactive groups in glycans, which 
can be useful in analyzing and imaging the glycome with fluorescent dyes and “click 
chemistry” variations (Prescher and Bertozzi, 2005, Du et al., 2009, Du and Yarema, 
2010, Almaraz et al., 2012). 
 
The stem cell glycocalyx can also be modified enzymatically ex vivo. Homing to 
bone marrow is initiated by tethering of the cells from circulation, followed by 
rolling on endothelial cell expressed P- and E-selectins (Figure 4). HSC rolling is 
mainly mediated by α1,3-fucosylated glycan determinants, such as sLex, that serve 
as selectin ligands. Treatment of UCB-CD34+ cells with guanosine diphosphate 
fucose (GDP-fucose) and exogenous α1,3-fucosyltransferase VI has been shown to 
increase cell-surface sLex determinants and augment binding to P- and E-selectins 
(Xia et al., 2004).  Enzymatic ex vivo fucosylation of MSCs similarly creates selectin 
ligands, directs the cells to bone marrow and primes them for transendothelial 
migration, which is needed for entry into the site of inflammation or injury 
(Sackstein et al., 2008, Thankamony and Sackstein, 2011).  
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3. AIMS OF THE STUDY 
Stem cells can be identified and isolated from various sources. However, there are no 
unique markers for different therapeutic stem cell populations and diverse panels of 
functional and phenotypical markers are used instead. Many commonly used stem 
cell markers are based on cell surface glycan epitopes. 
This study focused on the glycobiology of UCB derived therapeutic stem and 
progenitor cells. The original aims were to characterize unique features of UCB 
derived stem cell glycocalyxes by: 
 
 studying stem cell specific glycans and glycosyltransferases in UCB 
derived stem and progenitor cells  
 
 studying the possibility to modify stem cell surface glycosylation by 
metabolic glycoengineering 
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4. MATERIALS AND METHODS 
4.1 Methods 
The materials and methods used in this study are described in detail in the original 
publications and listed in Table 5. 
 
 Materials and methods used in the study. The original publications are referred to Table 5
using their Roman numerals I-V. 
Method Used in study 
Cell culture 
- isolation of mononuclear cells from UCB 
- cell differentiation 
- enzymatic treatment of cells 
I, II, III, IV,V 
I 
I, II, III, IV, V 
II, III, IV, V 
Flow cytometry 
-with antibodies 
-with lectins 
I, II, III, V 
I, II, V 
II, III, V 
Immunofluorescence microscopy I, II, III 
mRNA microarray analysis I, II, III, IV 
Reverse transcription polymerase chain reaction (RT-PCR) IV 
Quantitative real-time polymerase chain reaction (qRT-PCR) V 
Isolation of cell surface proteins II, III, V 
SDS-PAGE III, V 
Western blot V 
Mass spectrometry 
- analysis of lipid linked glycans 
- analysis of cell surface N-glycans 
- analysis of proteins 
- data-analysis 
I, II, III, V 
I 
II, V 
II, III 
I, II, III, V 
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4.2 Ethics 
This study was approved by the ethical review board of the Finnish Red Cross Blood 
Service and Helsinki University Hospital (statement numbers 550/E8/02 and 
235/13/03/00/2011). UCB was obtained after normal vaginal delivery with consent 
of informed and healthy volunteers at the Helsinki University Central Hospital, 
Department of Obstetrics and Gynaecology, and Helsinki Maternity Hospital. Only 
UCB units unsuitable for therapeutic use were used in these studies. The most 
common reason for discharging UCB units for therapeutic use was a small total 
volume or a low total number of cells. 
 
  
Method Used in study 
Enzyme-linked immunosorbent assay (ELISA) III 
Protein binding (pull-down) assay III 
Dissociation-enhanced lanthanide fluorescent immunoassay 
(DELFIA) 
IV 
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5. RESULTS   
The main results of the studies are summarised here. The results are presented and 
discussed in detail in the accompanying original publications, which are referred to 
using their Roman numerals I-V.  
5.1 Glycosyltransferases display characteristic expression 
patterns in umbilical cord blood stem and progenitor 
cells (I,II,IV) 
It is known that the expression of glycan epitopes on the cell surface can be 
correlated with the expression and activity levels of appropriate glycosyltransferases 
(Hemmoranta et al., 2007, Nairn et al., 2008). Therefore we studied the expression of 
several glycosyltransferases previously known to be involved in the synthesis of cell 
surface glycans in UCB derived stem and progenitor cells by analyzing mRNA 
expression levels. Data was retrieved both from an in-house-generated gene-
expression microarray data set and from public domain microarray expression data 
(Kilpinen et al., 2008). As expected, UCB derived stem and progenitor cells 
displayed the expression of a characteristic set of glycosyltransferases (I, II, IV).  
 
In the first instance we studied the expression glycosyltransferases involved in 
the synthesis of the widely used human embryonic stem cell markers SSEA-3 and 
SSEA-4 in UCB derived stem and progenitor cells (I). The expression of 
glycosyltransferases B3GalT-V (Beta-1,3-galactosyltransferase 5), ST3Gal-II (CMP-
N-acetylneuraminate-beta-galactosamide-alpha-2,3-sialyltransferase 2), FUT-1 (Ga-
lactoside 2-alpha-L-fucosyltransferase 1), and FUT-2 (Galactoside 2-alpha-L-
fucosyltransferase 2) was studied and the fold change of expression was compared to 
differentiated cells (I, Figure 2B). In UCB derived multipotent hematopoietic 
progenitor cells, positive for CD34 and CD133, a slight down-regulation was 
observed for all in comparison to CD34 negative and CD133 negative cells. In UCB-
MSCs the expression of SSEA-4 synthase ST3Gal-II was clearly elevated.  
 
Linear poly-LacNAc structures (blood group i antigen) have been shown to be 
enriched in bone marrow derived MSCs (Heiskanen et al., 2009). Therefore we 
studied the expression of the i antigen in UCB-MSCs (II).When we compared the 
fold changes of mRNA expression levels of glycosyltransferases involved in the 
synthesis of linear poly-LacNAc synthesis between UCB-MSCs and their 
differentiated counterparts, the highest fold change of expression was seen for 
ST3GAL-II, B3GNT5 (lactosylceramide1,3-N-acetyl-beta-D-glucosaminyltrans-
ferase), and B4GALT3 (beta-1,4-galactosyltransferase 3). A slight decrease in the 
fold change of expression of B4GALT4 (beta-1,4-galactosyltransferase 4), 
B4GALT5 (beta-1,4-galactosyltransferase 5) and iGnT (N-acetyllactosaminide beta-
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1,3-N-acetylglucosaminyltransferase) was also observed. We did not detect the 
expression of MGAT5 (Alpha-1,6-mannosylglycoprotein 6-beta-N-acetylglucose-
aminyltransferase A) or MGAT5b (Alpha-1,6-mannosylglycoprotein 6-beta-N-
acetylglucosaminyltransferase B). 
 
We also searched for other glycosyltransferase genes that would be enriched in 
stem cells. As a part of these studies we noticed a clear enrichment of the gene AER 
61, now known as EOGT (EGF domain-specific O-linked GlcNAc transferase) in 
stem cells (IV, Figure 1). EOGT expression was studied in different cell types and 
organs using public domain microarray expression data (Kilpinen et al., 2008). The 
highest relative gene expression levels were detected in MSCs, adult stem cells and 
HSCs compared to differentiated cell types and organs. A summary of highest 
differences detected in glycosyltransferase mRNA expression levels in UCB-MSCs 
is presented in Figure 9. 
 
 
 
 
Figure 9 Summary of highest fold change differences of mRNA expression levels from in-house 
microarray analysis for glycosyltransferase genes in UCB-MSCs. The expression levels in 
UCB-MSCs were compared to those in adipocytes (dark grey bars) and osteoblasts (light 
grey bars). 
5.2 Characterization of SSEA-3 and -4 cell surface 
expression in UCB stem and progenitor cells (I) 
The cell surface expression of SSEA-3, -4 and Globo-H was analyzed by flow 
cytometry utilizing commercially available antibodies. UCB-MSCs were found to be 
positive for SSEA-4 and negative for SSEA-3 and Globo-H (I, Figure 3). The cell 
surface localization was confirmed by immunofluorescence staining (I, Figure 4) and 
mass spectrometric analysis of lipid linked glycans from UCB-MSCs (I, Figure 5). 
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In order to study the hematopoietic progenitor cells of UCB, mononuclear cells were 
isolated and multipotent hematopoietic progenitor cells identified by positivity for 
cell surface markers CD34+ and CD133+. Freshly isolated hematopoietic progenitor 
cells gave a negative staining for SSEA-3, -4 and Globo-H (I, Figure 6).  
 
It is widely known that the expression of cell surface glycans is affected by cell 
source, methods used in isolation of cell populations and cell culture conditions. We 
noticed that fetal calf serum contains several glycosphingolipids (I, Figure 7) and 
studied further if culture conditions can affect the presentation of SSEA-3 or SSEA-
4 epitopes in UCB hematopoietic progenitor cells. We cultured the hematopoietic 
progenitor cells overnight in the presence of fetal calf serum and reanalysed the cells 
by flow cytometry (I, Figure 8). A clear elevation in SSEA-3 cell surface expression 
was observed.   
5.3 The i blood group antigen is a marker for UCB-MSCs (II) 
Linear poly-LacNAc structures (blood group i antigen) have been shown to be 
enriched in bone marrow derived MSCs so we studied the expression of the i antigen 
in UCB-MSCs. UCB-MSCs were stained with lectins and analysed by flow 
cytometry (II, Figure 1). STA, LEA and DSA (STA, Solanum tuberosum agglutinin; 
LEA, Lycopersicon esculentum agglutinin; DSA, Datura stramonium agglutinin) 
recognize mainly linear poly-LacNAc structures (i antigen), mitogen PWA 
(Phytolacca Americana agglutinin) recognizes mainly branched poly-LacNAc, and 
ECA (Erythrina cristagalli agglutinin) mainly terminal LacNAc structures. LEA, 
DSA and STA stained UCB-MSCs strongly, but also PWA and ECA stainings were 
positive to some extent. This indicates the presence of both linear and branched poly 
LacNAc structures in UCB-MSCs. The lectin binding properties of UCB-MSCs are 
summarized in Table 6. 
 Lectin binding properties of UCB-MSCs.  Table 6
Lectin 
UCB-MSC 
(% positive) 
STA 98% 
LEA 100% 
DSA 100% 
PWA 77% 
ECA 80% 
 
 
UCB-MSCs were also stained with human serum containing anti-i IgM 
immunoglobulins. The staining was 42-98% positive and disappeared after treatment 
with endo-β-galactosidase, an enzyme that hydrolyses internal β-galactosidic 
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linkages in oligosaccharides, as well as after differentiation of the cells towards 
adipogenic or osteogenic lineages (II, Figures 2 and 3). The results were further 
confirmed by mass spectrometric analysis of UCB-MSC surface N-glycans (II, 
Figure 4). The mass spectrometric analysis showed the presence of a biantennary N-
glycan with linear di-LacNAc epitope. 
5.4 Expression of galectins correlates with cell surface 
glycan expression in UCB-MSCs (II, III) 
Cell surface glycans exert their biological effects by binding to their cognate 
receptors, lectins. Galectins are a family of animal lectins that bind LacNAc 
containing glycans and are involved in various cellular processes. Since we showed 
the presence of both linear and branched poly LacNAc structures in UCB-MSCs, we 
also studied the expression of different galectins in UCB-MSCs by mRNA 
expression level profiling utilizing an in-house-generated gene-expression 
microarray data set (II, III). We discovered that UCB-MSCs express high levels of 
galectin-1 and -3 mRNA, the most abundant galectin mRNA being galectin-1 (III, 
Figure 4A). In addition, UCB-MSCs express galectins-8 and -9 with lower intensity. 
The relative gene expression level of galectin-3 was compared to the expression 
levels of previously known common MSC markers CD44, CD73, CD90, and CD105 
(II, Figure 6A). The relative gene expression level of galectin-3 was found to be 
significantly higher than the relative gene expression levels of the studied MSC 
markers.  
 
Galectins can be found both on the cell surface as well as inside the cells. Based 
on the gene expression data, we confirmed the cell surface localization of galectin-1 
(III, Figure 4B and C) and galectin-3 (II, Figure 6C) by flow cytometry and 
immunofluorescence stainings. We also performed mass spectrometric proteome 
analysis of biotinylated UCB-MSCs surface proteins and identified both galectin-1 
and -3 with a good protein identification score (II, Figure 6B, III, Figure 5C). 
Furthermore we showed that both incubation of UCB-MSCs in the presence of 
lactose (Galβ1-4Glc, a competing ligand for galectins) (III, Figure 6), and cell 
detachment from cell culture plates using pronase (a mixture of proteases isolated 
from the extracellular fluid of Streptomyces griseus) instead of conventional trypsin 
(III, Figure 2 and 5C), decreased the cell surface expression of galectins-1 and -3. 
When we compared the proteomes of trypsin and pronase treated cells, the most 
remarkable difference was seen in the expression of galectin-1. 
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5.5 UCB-MSCs display novel cell surface interactions (III) 
P-selectin has been reported to be a key mediator of MSC rolling on endothelial cells 
even though MSCs do not express known ligands for P-selectin (Ruster et al., 2006). 
P-selectin has been shown to bind to a PSGL-1 epitope containing sLex on a specific 
core-2-O-glycan with three adjacent sulphated tyrosine residues (Leppanen et al., 
2000) and weakly to some forms of heparin / heparin sulphate and other 
glycoproteins bearing the sLex determinant (Varki, 1994). We found that UCB-
MSCs stained 100% positive with a recombinant Fc-P-selectin chimera, even though 
these cells do not express PSGL-1, and that also naïve human P-selectin from 
thrombocyte lysate binds to UCB-MSCs (III, Figure 1). 
 
 We investigated this binding further by studying the expression of sLex epitopes 
on UCB-MSCs. We treated the cells with trypsin or pronase and performed a flow 
cytometric analysis (III, Figure 2). The expression of core-2-sLex and sLex epitopes 
remained mostly uninfluenced while the binding of the Fc-Pselectin chimera was 
clearly decreased in pronase treated cells. This indicated that P-selectin may bind to 
a novel ligand on UCB-MSCs. In order to identify the ligand, we performed a pull 
down assay and identified galectin-1 and galectin-3 as the binding partners (III, 
Figure 3A). The interaction between P-selectin and galectin-1 was further verified by 
ELISA (III, Figure 3B). We also showed that competitive removal of galectins from 
the cell surface by lactose decreased P-selectin binding to UCB-MSCs (III, Figure 
6). 
5.6 Expression of a novel cell surface glycan in stem cells 
(IV) 
It was recently found out that EOGT (EGF domain-specific O-linked GlcNAc 
transferase) O-GlcNAcylates EGF-domains on Drosophila Notch receptors 
(Matsuura et al., 2008). We noticed that EOGT mRNA is enriched in different stem 
and progenitor cell types (IV, Figure 1). We performed mRNA expression analysis 
of Notch receptors in UCB-MSCs as well as in UCB derived hematopoietic 
progenitor cells (positive for CD34 and CD133) by analysing mRNA expression 
levels from the in-house-generated gene-expression microarray data set (IV, Figure 
2A). UCB-MSCs expressed high levels of Notch-2 and -3 whereas the cells of 
hematopoietic origin, CD34+ and CD133+ cells, expressed mainly Notch-1 and -2. 
Moreover CD34+ and CD133+ cells expressed Notch-4 with a low intensity.  
 
In order to detect the presence of O-GlcNAc on the surface of UCB-MSCs, we 
performed DELFIA assays (IV, Figure 3B and C). We detected O-GlcNAc on cell 
surface using a commercial, well characterized, O-GlcNAc antibody (CTD110.6). 
However, when cells were treated with β-(1-4)-galactosidase the signal multiplied 
suggesting the presence of O-LacNAc. Treatment with O-GlcNAcase (OGA) 
abolished most of the signal. Treatment with both enzymes, -(1-4)-galactosidase 
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and OGA, resulted in a dose-dependent decrease in signal intensity indicating 
specific removal of O-LacNAc and O-GlcNAc.  
5.7 Metabolic glycoengineering of UCB-MSCs (V) 
Metabolic glycoengineering is a promising way to modify cell surface properties. 
We cultured UCB-MSCs in the presence of N-propanoylmannosamine (ManNProp). 
The mammalian biosynthetic machinery can tolerate this unnatural sialic acid 
precursor and incorporate it into cell surface glycoconjugates. We performed a mass 
spectrometric analysis of the ManNProp supplemented cells and noticed that half of 
Neu5Ac on cell surface N-glycans was replaced by Neu5Prop (V, Figures 4 and 5). 
In addition, ManNProp supplemented cells had more multiply fucosylated N-glycan 
species, and the amounts of tri- and tetra-antennary and polylactosamine containing 
N-glycans was increased, compared to unsupplemented control cells (V, Figure 6). 
The fucosylated epitopes were further shown to be Lewis x or blood group H 
epitopes by tandem mass spectrometric analysis. Furthermore, in flow cytometric 
assays using both lectins and anti glycan antibodies, we detected increased 
expression of sLex in ManNProp supplemented UCB-MSCs (V, Figure 1). The flow 
cytometric data was confirmed by western blot analysis (V, Figure 3). We did not 
detect sLex epitopes in the mass spectrometric analysis of N-glycans of ManNProp 
supplemented UCB-MSCs, therefore we believe that the sLex epitope is carried by 
O-glycans or glycolipids in these cells.   
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6. DISCUSSION   
UCB-derived stem cells harbour remarkable potential in therapeutic applications. 
Since the first successful transplantation of human UCB in 1988, a lot of effort has 
been put into understanding the biological features and the therapeutic use of UCB-
derived stem and progenitor cells. However, there still exists a great deal of open 
questions regarding the biochemical properties and the therapeutic use of these cells. 
Better tools are needed to characterize different cell populations in order to produce 
safe and defined cell preparations with a more predictable therapeutic outcome in 
stem cell based therapies. The main object of this study was to characterize umbilical 
cord blood derived stem cell surface glycan structures, to study how they are 
regulated and to determine their influence on stem cell biology as well as therapy.  
6.1 Glycosyltransferases as stem cell markers 
Gene expression profiling is a useful tool in understanding the genetic regulation of a 
particular cell type and expression profiling of glycosyltransferases can give 
valuable information on the glycome of a given cell type (Nairn et al., 2008). In this 
study it was elucidated if the expression of glycosyltransferase genes in UCB 
derived stem and progenitor cells correlates with the expression of glycan epitopes 
on the cell surface. We studied the expression profiles of specific 
glycosyltransferases known to be involved in the synthesis of stem and progenitor 
cell specific glycan determinants. 
 
In the first instance, we studied the expression of several glycosyltransferases 
involved in the synthesis of common stem cell markers SSEA-3 and SSEA-4 by 
mRNA expression profiling (I). It was clearly seen that the SSEA-4 synthase, 
ST3Gal-II, is enriched in UCB-MSCs as compared to differentiated cells. We could 
not detect enrichment for glycosyltransferases synthesising SSEA-3 and Globo-H, 
instead, these transferases were slightly down-regulated in all UCB stem and 
progenitor cell types studied. These results were in good correlation with our mass 
spectrometry studies that indicated the presence of SSEA-4 in UCB-MSCs, and our 
flow cytometric findings, that verified the absence of SSEA-3, 4, and Globo-H in 
UCB-HSCs and the presence of SSEA-4 in UCB-MSCs.  
 
Subsequently, we studied the expression of glycosyltranferases involved in the 
synthesis of linear poly-LacNAc (i antigen) (II) shown to be displayed by bone 
marrow-derived MSCs (Heiskanen et al., 2009). Poly-LacNAc structures are 
typically found in specific types of N-linked, O-linked and glycosphingolipid 
glycans. The expression of the i antigen is influenced by transferases synthesizing 
both the underlying backbone structures as well as the poly-LacNAc chain itself. 
MGAT5 gene expression has previously been shown to determine the expression of 
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poly-LacNAc on N-glycans (Pierce and Arango, 1986, van den Eijnden et al., 1988, 
Yousefi et al., 1991, Saito et al., 1994). We detected poly-LacNAc on biantennary 
N-glycans in MS analysis, however we did not detect the expression of either 
MGAT5 or MGAT5b mRNA. This indicates that the expression of the i antigen in 
N-glycans on UCB-MSCs is not dependent on MGAT5. Furthermore the expression 
of C2GNT (beta-1,3-galactosyl-O-glycosyl-glycoprotein beta-1,6-N-acetylglucos-
aminyltransferase 3), the gene encoding the transferase that can elongate the O-
glycan core 2 structure, was found to be low. Instead, we detected high expression 
levels of B3GNT5. Poly-LacNAc elongation occurs by the alternating action of B3-
N-acetylglucosaminyltransferases and B4-galactosyltransferases. B3GNT5 is both 
the initiator of neolactoseries glycosphingolipid biosynthesis as well as a poly-
LacNAc elongation enzyme. These results strongly suggest that the synthesis of 
linear poly-LacNAc in UCB-MSCs is independent of MGAT5 and mainly controlled 
by B3GNT5.  
 
 Moreover, we searched for genes encoding glycosyltransferases that would be 
enriched in stem cells (IV). We used public domain microarray expression data 
(Kilpinen et al., 2008) and discovered that EOGT mRNA is distinctively enriched in 
MSCs, adult stem cells and HSCs compared to differentiated cell types and organs. 
EOGT has lately been shown to be responsible for a novel type of glycosylation; it 
adds O-GlcNAc to extracellular protein EGF domains (Matsuura et al., 2008, 
Sakaidani et al., 2011, Sakaidani et al., 2012). We were also able to show the product 
of EOGT enzyme activity, O-GlcNAc, on UCB-MSCs in DELFIA analysis by a 
combination of several specific recognition reagents, including the use of as β-
galactosidase, O-GlcNAcase and a specific monoclonal antibody CDT110.6 in 
DELFIA analysis. 
 
Taken together, a correlation between expression profiling and the expression of 
glycan epitopes in UCB derived stem and progenitor cells was observed and novel 
characteristics of UCB-derived stem and progenitor cell glycosyltransferases were 
revealed. The most important finding was the expression of a recently characterized 
glycosyltransferase, EOGT, in stem cells. Also, the expression profiles of the studied 
glycosyltransferases are characteristic to UCB derived stem and progenitor cells, 
compared to cells differentiated from them, and reflect the complicated and strictly 
controlled biosynthesis events of UCB stem and progenitor cell glycocalyxes.  
 
The information gained on the expression of glycosyltransferases can be used in 
the characterization of different stem cell types from UCB as well as in quality 
control and evaluation of differentiation stage for therapeutic cell preparations. 
However, the expression glycosyltranferases does not reveal the activation or 
activity status of these enzymes or if they have access to their substrates in the cell. 
Therefore, a more profound enzyme activity analysis would be needed in order to 
specifically pinpoint the active enzymes. 
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6.2 Glycan epitopes as markers for umbilical cord blood 
derived stem and progenitor cells 
Stem cells are currently identified and characterized using panels of functional and 
phenotypical markers as single molecular markers do not comprehensively define a 
therapeutic stem cell.  Since the identification and isolation of stem cells is difficult, 
stem cell preparations consist of heterogeneous cell populations that vary between 
preparations and laboratories (Phinney, 2007, Schroeder, 2010). Cell surface glycans 
play an important role in the characterization of specific cell types and many stem 
cell markers are based on glycan epitopes.  
 
We studied the display of glycosphingolipid epitopes Globo-H, SSEA-3 and 
SSEA-4 in UCB derived stem and progenitor cells using flow cytometric assays (I). 
In accordance with our gene expression profiling data, UCB-HSCs were found not to 
express SSEA-3, -4 or Globo-H. UCB-MSCs were found positive for SSEA-4 and 
negative for SSEA-3 and Globo-H. UCB-MSCs are a rare cell population and need 
to be expanded ex vivo in order to produce a therapeutically relevant amount of 
MSCs. It is well known that culture conditions affect cell surface glycans, and 
metabolically incorporated non-human glycans may contaminate cells (Qian et al., 
2012, Martin et al., 2005, Heiskanen et al., 2007). We studied if cell culture media 
and fetal calf serum in particular, affects the display of SSEA-3 and SSEA-4 
epitopes in UCB-HSCs. We detected a clear elevation in the presentation of SSEA-3 
after exposure to fetal calf serum. Several different mechanisms including induction 
of glycosyltransferase gene expression, incorporation of glycolipids from cell culture 
media, differential expansion of minor cell populations or cell culture media induced 
activation of biosynthetic enzymes and glycosyltransferases, may have contributed 
to this altered cell surface epitope presentation. However, this change in the cell 
surface expression of globoseries glycosphingolipids underlines the importance of 
strictly controlled cell culture conditions on the properties of therapeutic cells. Minor 
changes on the cell surface epitopes of therapeutic cells may critically alter the 
therapeutic outcome.  
 
The isolation of MSCs from UCB and other sources relies on the adherence 
properties of the cells due to the lack of molecular markers that could be used in the 
isolation. The result of inefficient isolation protocols is a heterogenous population of 
stem, progenitor, precursor and other cells (Phinney, 2007). Linear poly-LacNAc (i 
antigen) has been shown to be enriched in bone marrow-MSCs (Heiskanen et al., 
2009). We studied the expression of linear poly-LacNAc in UCB-MSCs (II). Our 
studies indicated that in UCB-MSCs linear poly-LacNAc is carried by N-glycans, at 
least in biantennary structures. However, further studies are required in order to 
determine whether it is also carried by glycosphingolipids and O-glycans in these 
cells. Based on our studies, linear poly-LacNAc could be used as a MSC marker in 
the identification and isolation of UCB-MSCs as a part of the previously 
characterized panels of cell surface markers.   
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Our gene expression profiling data of different types of stem cells indicated the 
expression of EOGT, a glycosyltransferase that is dedicated to adding O-GlcNAc to 
folded EGF domains on extracellular protein domains (IV) (Sakaidani et al., 2011). 
In correlation with the gene expression profiling, we were able to detect the 
enzymatic reaction product of EOGT, O-GlcNAc, by DELFIA analysis on UCB-
MSC surface. Moreover, we discovered that the O-GlcNAc is further elongated to 
O-LacNAc by the addition of galactose. The elongation of O-GlcNAc to O-LacNAc 
has also been suggested previously by (Sakaidani et al., 2012).  This type of 
glycosylation is however a novel concept both in the field of cell surface 
glycosylation and stem cell surface markers, and warrants further studies in order to 
elucidate its biological role.    
 
In accordance with the newly discovered glycan determinants, O-LacNAc and 
linear poly-LacNAc, on UCB-MSCs, we also detected galectins-1 and -3, two 
mammalian lectins that cross-link glycoproteins bearing LacNAc units, on UCB-
MSC surface (II, III). Galectins play a pivotal role in MSC mediated 
immunomodulation of innate and adaptive immune responses. Previously, galectins-
1 and -3 have been shown to be key players in MSC immunomodulatory effects 
(Gieseke et al., 2010, Sioud et al., 2011), and it has been suggested that especially 
galectins-3 and -9 could be used as potential biomarkers to predict the 
immunomodulatory potential of therapeutic MSC preparations (Liu et al., 2013, 
Ungerer et al., 2013). The sequestration of galectin-1 and galectin-3 on the cell 
surface can be considered a characteristic feature of UCB-MSCs. 
 
The discovery of novel stem cell surface markers enables better characterization 
of therapeutic stem cell populations. Safe and defined cell preparations are required 
for therapy as well as for research purposes. In order to create safe therapeutic cells, 
even minor changes in cells should be identified and discrepancies between variable 
cell isolation protocols and differential cell culture conditions in different 
laboratories need to be minimized. Cell surface glycan epitopes can be used to 
develop glycan binders for isolation of different cell populations, as well as to 
analyze cellular differentiation, to detect the presence of xenocontamination, to 
characterize migratory properties of cells, and to evaluate cell viability. Anti-glycan 
antibodies can also be used to fractionate stem cell transplants into differently 
therapeutic cellular subpopulations, to isolate and enrich beneficial cell types, or to 
remove undesired cells. Our results indicate also that the current panels of stem cell 
markers may not comprehensively define different therapeutic stem cell populations. 
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6.3 Glycans in stem cell therapy 
 
A major obstacle in stem cell therapy is the inefficient homing of transplanted 
cells to desired organs and tissues. Stem cell homing is a sequential process and a 
result of a cascade of rolling, activation, and adhesion events that requires a complex 
interplay between chemokines, chemokine receptors, intracellular signaling, 
adhesion molecules and proteases (Henschler et al., 2008). It is believed that MSC 
homing to inflamed or injured tissues is beneficial for their paracrine effects, but the 
exact role and mechanisms of MSC homing are still not completely understood 
(Sohni and Verfaillie, 2013). We discovered that galectins-1 and -3 on MSC surface 
interact with P-selectin, a key player in MSC homing (III). Further functional studies 
are required in order to elucidate the exact role of this novel interaction in the 
sequential steps of the homing process. However, this novel interaction is likely to 
participate in the recruitment of MSCs from circulation to sites of inflammation or 
injury, and thereby participate in the immunomodulatory targeting of these cells.  
 
Cell type specific glycan features can be utilized and modified when creating 
therapeutic cell populations for medical use. The properties of therapeutic cells and 
cell populations could for example be altered to reduce immunogenity, to influence 
proliferation, or to enhance their biodistribution. Changes in cell surfce glycosylation 
can be achieved by changing cell culture conditions (metabolic glycoengineering) 
(Campbell et al., 2007a). In this study, we present the effects of metabolic 
glycoengineering of UCB-MSC with N-propanoylmannosamine (ManNProp) (V). 
The present results represent the first structural analysis on an N-glycome of 
glycoengineered cells, and demonstrate the feasibility of altering cell surface 
glycosylation of therapeutic cells by this type of methodology. We discovered that in 
ManNProp supplemented cells half of Neu5Ac on cell surface N-glycans was 
replaced by Neu5Prop. Furthermore we detected changes in the N-glycan profile of 
the supplemented cells. The amounts of tri- and tetra-antennary and polylactosamine 
containing N-glycans was increased and ManNProp supplemented cells had more 
multiply fucosylated N-glycan species and sLex structures compared to 
unsupplemented control cells. Taken together, metabolic glycoengineering is a 
promising and robust way to alter the properties of therapeutic cells.  
6.4 Concluding remarks 
 
The original aims of these studies were to characterize stem cell specific glycans 
and glycosyltransferases in UCB derived stem and progenitor cells and to explore 
the possibility to modify stem cell surface glycosylation by metabolic 
glycoengineering. By glycosyltransferase gene expression profiling and cell surface 
analysis we discovered unique features of UCB derived stem cell glycocalyxes, 
including two novel glycan determinants, extracellular O-GlcNAc and linear poly-
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LacNAc on UCB-MSCs. We also discovered that the expression of the common 
stem cell marker SSEA-3 is affected by cell culture conditions. Furthermore, we 
characterized a novel interaction between galectin-1 and P-selectin and showed by 
structural glycan analysis that cell surface glycosylation can be efficiently altered by 
metabolic glycoengineering. In conclusion, these studies have provided novel 
insights into the glycobiology of UCB derived stem and progenitor cells that may 
help to distinguish better cell populations for distinct therapeutic applications and to 
design therapeutic cells with enhanced biological properties.  
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